Zogenix, Inc. (NASDAQ:ZGNX) CFO Michael P. Smith sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $50.00, for a total value of $750,000.00. Following the completion of the transaction, the chief financial officer now directly owns 16,387 shares in the company, valued at $819,350. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Michael P. Smith also recently made the following trade(s):

  • On Thursday, June 27th, Michael P. Smith sold 15,000 shares of Zogenix stock. The shares were sold at an average price of $46.32, for a total value of $694,800.00.

ZGNX stock traded down $0.37 during trading on Monday, hitting $49.61. The company had a trading volume of 263,471 shares, compared to its average volume of 606,700. The firm’s fifty day moving average is $47.59. The company has a current ratio of 7.19, a quick ratio of 9.12 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $2.10 billion, a P/E ratio of -15.36 and a beta of 1.92. Zogenix, Inc. has a fifty-two week low of $33.43 and a fifty-two week high of $56.50.

Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.89) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.06). The company had revenue of $1.07 million during the quarter, compared to analyst estimates of $15.00 million. During the same quarter last year, the company posted ($0.83) earnings per share. As a group, analysts expect that Zogenix, Inc. will post -3.76 earnings per share for the current year.

A number of research analysts recently weighed in on ZGNX shares. Mizuho raised their price objective on Zogenix from $58.00 to $65.00 and gave the company a “positive” rating in a research note on Friday, June 28th. ValuEngine raised Zogenix from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Guggenheim raised Zogenix from a “neutral” rating to a “buy” rating and raised their target price for the company from $40.00 to $64.00 in a report on Thursday, June 27th. Northland Securities reaffirmed a “buy” rating and issued a $60.00 target price on shares of Zogenix in a report on Monday, July 8th. Finally, BidaskClub raised Zogenix from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $63.55.

Institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc raised its position in shares of Zogenix by 13.0% during the fourth quarter. Legal & General Group Plc now owns 7,848 shares of the company’s stock worth $286,000 after acquiring an additional 900 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Zogenix by 102.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 470,460 shares of the company’s stock valued at $17,152,000 after buying an additional 238,002 shares during the period. Atika Capital Management LLC boosted its position in Zogenix by 90.0% during the first quarter. Atika Capital Management LLC now owns 76,000 shares of the company’s stock valued at $4,181,000 after buying an additional 36,000 shares during the period. Teacher Retirement System of Texas purchased a new stake in Zogenix during the first quarter valued at about $7,575,000. Finally, Parametrica Management Ltd purchased a new stake in Zogenix during the first quarter valued at about $222,000.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Featured Story: Beta

Insider Buying and Selling by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.